NEW ORLEANS — Real-world results of the TRUCKEE study at 4.5 years showed that faricimab was “safe, efficacious and improved anatomy” in patients with wet age-related macular degeneration.
In this video from the American Academy of Ophthalmology meeting, Carl J. Danzig, MD, of Fort Lauderdale Eye Institute, patients with wet AMD who switched from anti-VEGF therapy to Vabysmo (faricimab, Genentech) were able to extend the injection interval by nearly 2 weeks after nine injections, whereas treatment-naive patients were able to achieve injection intervals of 10 to 11 weeks after approximately 10